Shares of Pyxis Oncology, Inc. (NASDAQ:PYXS – Get Free Report) have been given an average recommendation of “Moderate Buy” by the ten research firms that are covering the firm, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and eight have given a buy rating to the company. The average 12-month price objective among analysts that have updated their coverage on the stock in the last year is $8.75.
Several brokerages have commented on PYXS. Wells Fargo & Company upped their target price on shares of Pyxis Oncology from $12.00 to $19.00 and gave the company an “overweight” rating in a research note on Wednesday, September 9th. Weiss Ratings reissued a “sell (e+)” rating on shares of Pyxis Oncology in a research report on Friday, September 25th. HC Wainwright boosted their price target on shares of Pyxis Oncology from $7.00 to $8.00 and gave the company a “buy” rating in a report on Thursday, September 10th. Leerink Partners lowered their price objective on shares of Pyxis Oncology from $9.00 to $7.00 and set an “outperform” rating for the company in a research report on Thursday, July 2nd. Finally, Wedbush raised their price objective on Pyxis Oncology from $6.00 to $8.00 and gave the stock an “outperform” rating in a research note on Thursday, September 10th.
Get Our Latest Research Report on Pyxis Oncology
Institutional Inflows and Outflows
Pyxis Oncology Trading Down 9.8%
Pyxis Oncology stock opened at $2.02 on Friday. The firm has a market capitalization of $168.48 million, a P/E ratio of -1.43 and a beta of 1.37. Pyxis Oncology has a 1 year low of $1.03 and a 1 year high of $5.55. The business has a 50-day moving average of $3.14 and a 200-day moving average of $2.41.
Pyxis Oncology (NASDAQ:PYXS – Get Free Report) last announced its quarterly earnings results on Thursday, August 13th. The company reported ($0.40) EPS for the quarter, missing analysts’ consensus estimates of ($0.35) by ($0.05). Research analysts anticipate that Pyxis Oncology will post -1.21 EPS for the current fiscal year.
About Pyxis Oncology
Pyxis Oncology, Inc (NASDAQ: PYXS) is a clinical-stage biotechnology company developing therapies for cancer. The company focuses on treatments designed to address both tumor cells and the tumor microenvironment, with the goal of improving the effectiveness of the immune system and other anticancer mechanisms against solid tumors.
Its research and development programs include antibody-drug conjugates and immunotherapies. Pyxis Oncology’s lead program, PYX-201, is an antibody-drug conjugate designed to target the extradomain B form of fibronectin, a protein found in the tumor microenvironment, and deliver an anticancer payload to tumor tissue.
Featured Stories
- Five stocks we like better than Pyxis Oncology
- Constellation Energy’s Google Deal Shows Why Nuclear Uprates Matter for AI
- Lamb Weston’s Turnaround Is Starting to Look Real
- These 3 Stocks Got the Most Love From Analysts in September
- Record French Debt Could Create Opportunities for U.S. Market Operators
Receive News & Ratings for Pyxis Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pyxis Oncology and related companies with MarketBeat.com's FREE daily email newsletter.
